ERBB2 and breast carcinoma: Using U937 monocytic effector cells 101, trastuzumab IgG1 mediated killing of HER2‐overexpressing CT26 murine as well as of SKBR3 human mammary carcinoma cells mainly by ADCP, whereas trastuzumab IgE mediated killing via ADCC 99.